Aleksandra Markovets

2.6k total citations · 4 hit papers
39 papers, 1.4k citations indexed

About

Aleksandra Markovets is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Aleksandra Markovets has authored 39 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 19 papers in Cancer Research. Recurrent topics in Aleksandra Markovets's work include Lung Cancer Treatments and Mutations (30 papers), Cancer Genomics and Diagnostics (18 papers) and Colorectal Cancer Treatments and Studies (14 papers). Aleksandra Markovets is often cited by papers focused on Lung Cancer Treatments and Mutations (30 papers), Cancer Genomics and Diagnostics (18 papers) and Colorectal Cancer Treatments and Studies (14 papers). Aleksandra Markovets collaborates with scholars based in United States, United Kingdom and South Korea. Aleksandra Markovets's co-authors include J. Carl Barrett, Suresh S. Ramalingam, Yuri Rukazenkov, Kenneth S. Thress, Juliann Chmielecki, James Chih‐Hsin Yang, Byoung Chul Cho, Daniel Stetson, Yuichiro Ohe and Thomas John and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Aleksandra Markovets

36 papers receiving 1.4k citations

Hit Papers

Osimertinib As First-Line... 2017 2026 2020 2023 2017 2018 2023 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
    2017 380 citations Suresh S. Ramalingam, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
  2. Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
    2018 269 citations Suresh S. Ramalingam, Yi Cheng et al. Annals of Oncology profile →
  3. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
    2023 130 citations Juliann Chmielecki, Jhanelle E. Gray et al. Nature Communications profile →
  4. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON
    2022 95 citations Ryan J. Hartmaier, Aleksandra Markovets et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aleksandra Markovets United States 16 1.1k 834 573 392 127 39 1.4k
J. A. Engelman United States 12 1.0k 0.9× 834 1.0× 511 0.9× 257 0.7× 119 0.9× 24 1.3k
Xiaoqing Liu China 19 1.0k 0.9× 916 1.1× 407 0.7× 462 1.2× 123 1.0× 70 1.5k
Alexandra Voutsina Greece 17 624 0.6× 682 0.8× 491 0.9× 410 1.0× 135 1.1× 31 1.2k
Jaromı́r Roubec Czechia 9 1.3k 1.1× 1.3k 1.5× 574 1.0× 170 0.4× 75 0.6× 23 1.7k
Michèle Beau‐Faller France 22 1.6k 1.4× 1.3k 1.6× 758 1.3× 554 1.4× 156 1.2× 61 2.1k
Ryan S. Alden United States 10 1.2k 1.1× 719 0.9× 457 0.8× 1.0k 2.7× 264 2.1× 14 1.5k
Erzsébet Juhász Hungary 15 1.1k 0.9× 1.2k 1.4× 568 1.0× 235 0.6× 93 0.7× 28 1.7k
Julia Rotow United States 14 654 0.6× 609 0.7× 582 1.0× 316 0.8× 85 0.7× 47 1.1k
Nora Feeney United States 8 1.1k 1.0× 772 0.9× 516 0.9× 959 2.4× 245 1.9× 11 1.5k
Ira A. Oliff United States 8 1.2k 1.1× 1.3k 1.5× 451 0.8× 226 0.6× 61 0.5× 12 1.7k

Countries citing papers authored by Aleksandra Markovets

Since Specialization
Citations

This map shows the geographic impact of Aleksandra Markovets's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aleksandra Markovets with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aleksandra Markovets more than expected).

Fields of papers citing papers by Aleksandra Markovets

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aleksandra Markovets. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aleksandra Markovets. The network helps show where Aleksandra Markovets may publish in the future.

Co-authorship network of co-authors of Aleksandra Markovets

This figure shows the co-authorship network connecting the top 25 collaborators of Aleksandra Markovets. A scholar is included among the top collaborators of Aleksandra Markovets based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aleksandra Markovets. Aleksandra Markovets is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
John, Thomas, Christian Grohé, Jonathan W. Goldman, et al.. (2024). Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8005–8005. 15 indexed citations
2.
Grazini, Ursula, Aleksandra Markovets, Lucy Ireland, et al.. (2024). Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations. Clinical Cancer Research. 30(18). 4143–4154. 12 indexed citations
3.
Jänne, Pasi A., Kunihiko Kobayashi, Jacqulyne Robichaux, et al.. (2024). Abstract CT017: FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed. Cancer Research. 84(7_Supplement). CT017–CT017. 13 indexed citations
4.
Gray, Jhanelle E., Aleksandra Markovets, Thanyanan Reungwetwattana, et al.. (2024). Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3. Journal of Thoracic Oncology. 19(11). 1525–1538. 5 indexed citations
5.
Chmielecki, Juliann, Jhanelle E. Gray, Ying Cheng, et al.. (2023). Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 14(1). 1070–1070. 130 indexed citations breakdown →
6.
Suárez, Cristina, James Larkin, Begoña P. Valderrama, et al.. (2023). Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO). Journal of Clinical Oncology. 41(14). 2493–2502. 35 indexed citations
7.
8.
Hartmaier, Ryan J., Aleksandra Markovets, Myung‐Ju Ahn, et al.. (2022). Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON. Cancer Discovery. 13(1). 98–113. 95 indexed citations breakdown →
9.
Criscione, Steven W., Matthew J. Martin, Derek B. Oien, et al.. (2022). The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells. npj Precision Oncology. 6(1). 95–95. 22 indexed citations
10.
Lim, Sun Min, Sangbin Lim, Seong Gu Heo, et al.. (2022). Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models. Therapeutic Advances in Medical Oncology. 14. 4287491157–4287491157. 14 indexed citations
11.
Vaclová, Tereza, Ursula Grazini, Lewis S. C. Ward, et al.. (2021). Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. Nature Communications. 12(1). 1780–1780. 46 indexed citations
12.
Hsu, Chia‐Chi, Bin-Chi Liao, Wei‐Yu Liao, et al.. (2019). Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 15(1). 50–61. 61 indexed citations
13.
Brown, Helen, Johan Vansteenkiste, Kazuhiko Nakagawa, et al.. (2019). Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. Journal of Thoracic Oncology. 15(1). 138–143. 38 indexed citations
14.
Sale, Matthew J., Noel R. Monks, Rebecca Gilley, et al.. (2019). Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors. Nature Communications. 10(1). 5167–5167. 51 indexed citations
15.
Frigault, Melanie M., Sabina Signoretti, Aleksandra Markovets, et al.. (2018). Abstract 4541: MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor. Cancer Research. 78(13_Supplement). 4541–4541. 2 indexed citations
16.
Ramalingam, Suresh S., Yi Cheng, C. Zhou, et al.. (2018). Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. Annals of Oncology. 29. viii740–viii740. 269 indexed citations breakdown →
17.
Brown, Heather A., Johan Vansteenkiste, Kazuhiko Nakagawa, et al.. (2018). MA15.03 PD-L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR-TKIs in the FLAURA Trial. Journal of Thoracic Oncology. 13(10). S408–S408. 3 indexed citations
18.
Cho, Byoung Chul, Changdong Zhou, Fumio Imamura, et al.. (2018). Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. Annals of Oncology. 29. ix177–ix177. 28 indexed citations
19.
Ahn, Myung‐Ju, Ji‐Youn Han, Chun‐Ming Tsai, et al.. (2017). OA 10.01 Detection of EGFR mutations from plasma ctDNA in the osimertinib Phase III trial (AURA3): comparison of three plasma assays. Journal of Thoracic Oncology. 12(11). S1771–S1771. 5 indexed citations
20.
Markovets, Aleksandra & Damir Herman. (2011). Analysis of cancer metabolism with high-throughput technologies. BMC Bioinformatics. 12(S10). S8–S8. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. A. Engelman Breakdown of academic impact, for papers by Xiaoqing Liu Breakdown of academic impact, for papers by Alexandra Voutsina Breakdown of academic impact, for papers by Jaromı́r Roubec Breakdown of academic impact, for papers by Michèle Beau‐Faller Breakdown of academic impact, for papers by Ryan S. Alden Breakdown of academic impact, for papers by Erzsébet Juhász Breakdown of academic impact, for papers by Julia Rotow Breakdown of academic impact, for papers by Nora Feeney Breakdown of academic impact, for papers by Ira A. Oliff
Rankless by CCL
2026